Current status of HER2 testing: Caught between a rock and a hard place

American Journal of Clinical Pathology

Volumn 116, Issue 6, 2001, Pages 806-810

  Schnitt, S J ^a   Jacobs, T W ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER SCREENING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035189256     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/WMN8-VTR5-DUGF-X12L     Document Type: Note

References (24)

1. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer
2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
3. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
4. Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside
5. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999
6. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
7. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
8. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration - Approved scoring system
9. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
10. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
11. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohisto-chemistry
12. Interpretation and quantification of immunostains
13. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
14. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry
15. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
16. Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieved high accuracy in comparison with fluorescence in situ hybridization assay as the standard
17. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis
18. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer: The Quicgel method
19. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
20. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
21. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
22. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy
23. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
24. HER-2/neu protein expression in breast cancer evaluated by immunohisto-chemistry: A study of interlaboratory agreement